ArticleBMC medical imaging2026
Non-Gaussian diffusion MRI using CTRW and FROC models for early treatment response assessment in nasopharyngeal carcinoma.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the efficacy of virtual magnetic resonance elastography and continuous-time random walk models in predicting clinically significant prostate cancer.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo evaluate the utility of non-Gaussian diffusion parameters derived from the continuous-time random walk (CTRW) and fractional order calculus (FROC) models for early treatment response assessment in nasopharyngeal carcinoma (NPC) and to compare their performance with the apparent diffusion coefficient (ADC).
methodsDiffusion-weighted imaging (DWI) with 13 b-values was performed before and during early treatment in 61 patients with newly diagnosed NPC. Parameters derived from the CTRW and FROC models (DCTRW, αCTRW, βCTRW, DFROC, βFROC, µFROC) and ADC, along with their percentage changes, were compared between residual and non-residual groups after concurrent chemoradiotherapy (CCRT) with (n = 56) or without (n = 5) induction chemotherapy (IC), and between partial responders and stable disease groups in the IC subgroup. Group comparisons were performed using the Mann–Whitney U test or t-test, and predictive performance was evaluated using receiver operating characteristic (ROC) and logistic regression analyses.
resultsFor IC response, Pre-βFROC, Pre-µFROC, and Pre-βCTRW significantly differentiated partial responders from stable disease groups, with Pre-βFROC demonstrating the highest discriminatory performance (AUC = 0.798). A combined model incorporating βCTRW and µFROC further improved prediction (AUC = 0.817). For the CCRT outcome, several Pre- and Δ% parameters differed significantly between residual and non-residual groups. ΔβCTRW% achieved the highest diagnostic accuracy (AUC = 0.822), while combining ΔβCTRW% with ΔADC% yielded the best overall performance (AUC = 0.878).
conclusionsDiffusion parameters derived from the CTRW and FROC models provide sensitive markers of microstructural heterogeneity in NPC and outperform conventional ADC in early treatment evaluation. Pre-βFROC, Pre-µFROC, and Pre-βCTRW are valuable for predicting IC response, whereas ΔβCTRW% shows strong potential for identifying residual tumor after CCRT. Combined predictive models further enhance diagnostic accuracy, supporting non-Gaussian diffusion imaging as a promising biomarker for early efficacy assessment and personalized management of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.